ArticleInternational journal of nanomedicine2018
Praziquantel-lipid nanocapsules: an oral nanotherapeutic with potential
Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 49 citations in OpenAlex.
- Mannosylated fisetin/carveol lipid nanocapsules: brain-targeted dual therapy for modulation of epileptogenesis and cognitive deficits.Drug delivery and translational research · 2026Article
- Antiparasitic triterpenic ester and ursolic acid lipid nanocapsule design, cytotoxicity, and permeability evaluation for oral delivery.Frontiers in drug delivery · 2026Article
- Quantification and Engineering of Lipid Nanocapsule Formulations for the Delivery of Niclosamide as an Anti-Cancer Drug.Current pharmaceutical design · 2026Article
- Nanotechnology based approaches to the treatment of schistosomiasis: current status and future perspectives.Nanomedicine (London, England) · 2025Review
- Prophylactic effect of nano vitamin D3 against fatty degeneration caused by calcium-deficient diet in parotid salivary gland: a histological and ultrastructural study.BMC oral health · 2025Article
- Brain targeted lactoferrin coated lipid nanocapsules for the combined effects of apocynin and lavender essential oil in PTZ induced seizures.Drug delivery and translational research · 2025Article
- Nanomaterials as a Potential Target for Infectious Parasitic Agents.Current drug delivery · 2024Review
- Nanotechnological approaches in the treatment of schistosomiasis: an overview.Beilstein journal of nanotechnology · 2024Review
- The Idiosyncratic Efficacy of Spironolactone-Loaded PLGA Nanoparticles Against Murine Intestinal Schistosomiasis.International journal of nanomedicine · 2023Article
- Nanoparticles as Potent Agents for Treatment ofCurrent therapeutic research, clinical and experimental · 2023Review
- Histopathological, physiological and biochemical assessment of resveratrol nanocapsules efficacy in bleomycin-induced acute and chronic lung injury in rats.Drug delivery · 2022Article
- Tunable Polymeric Mixed Micellar Nanoassemblies of Lutrol F127/Gelucire 44/14 for Oral Delivery of Praziquantel: A Promising Nanovector againstPharmaceutics · 2022Article
- In Vivo Evaluation of an Antibody-Functionalized Lipoidal Nanosystem for Schistosomiasis Intervention.Pharmaceutics · 2022Article
- Therapeutic Efficacy of Carvacrol-Loaded Nanoemulsion in a Mouse Model of Schistosomiasis.Frontiers in pharmacology · 2022Article
- Potential application of nanotechnology in the treatment, diagnosis, and prevention of schistosomiasis.Frontiers in bioengineering and biotechnology · 2022Review
- The Effect of Different Formulations of Praziquantel in Reducing Worms in the Prepatent Period of Schistosomiasis in Murine Models.Frontiers in public health · 2022Article
- New In Vitro Coculture Model for Evaluating Intestinal Absorption of Different Lipid Nanocapsules.Pharmaceutics · 2021Article
- Cyclosporine Lipid Nanocapsules as Thermoresponsive Gel for Dry Eye Management: Promising Corneal Mucoadhesion, Biodistribution and Preclinical Efficacy in Rabbits.Pharmaceutics · 2021Article
- Modified Lipid Nanocapsules for Targeted Tanshinone IIA Delivery in Liver Fibrosis.International journal of nanomedicine · 2021Article
- Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni.Parasites & vectors · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLipid nanocapsules (LNCs) have shown potential to increase the bioavailability and efficacy of orally administered drugs. However, their intestinal translocation to distal target sites and their implication in pharmacokinetic (PK)-pharmacodynamic (PD) relationships are yet to be elucidated. In this study, the effect of LNCs on the PD activity and pharmacokinetics of praziquantel (PZQ), the mainstay of schistosomiasis chemotherapy, was investigated. MATERIALS AND
methodsThe composition of LNCs was modified to increase PZQ payload and to enhance membrane permeability. PZQ-LNCs were characterized in vitro for colloidal properties, entrapment efficiency (EE%), and drug release. PD activity of the test formulations was assessed in
resultsPZQ-LNCs exhibited good pharmaceutical attributes in terms of size (46-62 nm), polydispersity index (0.01-0.08), EE% (>95%), and sustained release profiles. Results indicated significant efficacy enhancement by reduction in worm burden, amelioration of liver pathology, and extensive damage to the fluke suckers and tegument. This was partly explained by PK data determined in rats. In addition, oral targeting of the worms was supported by the stability of PZQ-LNCs in simulated GI fluids and scanning electron microscopy (SEM) visualization of nanostructures on the tegument of worms recovered from mesenteric/hepatic veins. Cytotoxicity data indicated tolerability of PZQ-LNCs.
conclusionData obtained provide evidence for the ability of oral LNCs to target distal post-absorption sites, leading to enhanced drug efficacy. From a practical standpoint, PZQ-LNCs could be suggested as a potential tolerable single lower dose oral nanomedicine for more effective PZQ mass chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.